Gene Editing Institute Advancing Gene Editing and Genome Engineering for More Than 20 Years

The mission of the Gene Editing Institute is to elucidate the mechanism and regulation of genome editing at the molecular level and to help translate our results into clinically relevant applications. We employ single-stranded oligonucleotides and programmable nucleases, including TALENs and CRISPRS, as genetic tools to direct nucleotide exchange at specific sites within the mammalian genome. We use primary and model cell systems to study how gene editing takes place and to identify the activators and suppressors that control the reaction.

The ASCO Daily News featured an article by Eric Kmiec, Ph.D., director of the Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System, on gene editing using CRISPR/Cas 9 in human cells.

For its enormous potential to accelerate the development of personalized cancer therapies, the Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute has been awarded a grant of $900,000 from the U.S.-Israel Binational Industrial Research and Development (BIRD) Foundation in partnership with the biotechnology company NovellusDx.

Dr. Eric Kmiec spoke to the discovery by scientists of how to edit genes in embryos.

Delaware Business Times highlighted the efforts Dr. Eric Kmiec and Christiana Care to treat lung cancer with gene editing through a partnership with Israel-based NovellusDX.

To accelerate the development of next-generation cancer therapies, the Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System has agreed to provide genetically modified cell lines to Analytical Biological Services, Inc. (ABS) of Wilmington, Delaware.

$1 million NSF grant propels Delaware to forefront of gene editing education.

The Philadelphia-Israel Chamber of Commerce is presenting the first Life Science and Bio Innovation Award to the Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, for receiving The Life Science and Bio-Innovation Award from the Philadelphia-Israel Chamber of Commerce on May 22 at The Crystal Tea Room in Philadelphia.

Eric Kmiec, Ph.D., of the Gene Editing Institute will speak at the Lung Cancer Symposium at Christiana Hospital in Newark, Delaware on April 16.

Translation of our work will lead to the development of effective therapeutics for the treatment of inherited diseases as well as for the creation of credible and robust cell lines that can be used for the screening of novel anticancer drugs.

For more information, call 302-623-4761 or e-mail

20 Years of Discovery in Gene Editing

The Gene Editing Institute is widely recognized as a pioneering laboratory in the field of gene editing both in lower and higher eukaryotes. Over the course of the last 20 years, the Institute has focused on understanding the basic mechanism and regulation of gene editing within the context of the chromosome. These investigations, detailed in the above timeline, included analysis at the biochemical, molecular and cellular levels and generated a series of discoveries that led to the eventual development of specialized oligonucleotides (chimeras) that could direct targeted gene correction. These observations led to the conceptualization of the process of gene editing in mammalian cells.